# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Iridocorneal endothelial syndrome

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-8 of 8 results.
Study of Endothelial Keratoplasty Outcomes
Status: Completed
Last Changed: Jan 23, 2019
First Received: Dec 01, 2008
Disease(s): Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy
Intervention(s): endothelial keratoplasty
Locations: Price Vision Group, Indianapolis, Indiana, United States
Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
Status: Unknown status
Last Changed: Dec 24, 2013
First Received: Dec 24, 2013
Disease(s): Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy, Endothelial Dysfunction
Intervention(s): Endothelial Keratoplasty
Locations: Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Zhongshan Iridocorneal Endothelial Syndrome Study (ICEs)
Status: Recruiting
Last Changed: Apr 16, 2019
First Received: Sep 01, 2017
Disease(s): Glaucoma
Locations: Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Status: Completed
Last Changed: Jul 19, 2019
First Received: Jan 12, 2016
Disease(s): Fuchs' Corneal Endothelial Dystrophy (FCED)
Intervention(s): Elamipretide 1.0% Ophthalmic Solution, Elamipretide 3.0% Ophthalmic Solution
Locations: Cincinnati Eye Institute, Edgewood, Kentucky, United States
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Status: Recruiting
Last Changed: Sep 25, 2020
First Received: Aug 20, 2020
Disease(s): Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Intervention(s): TTHX1114(NM141), Vehicle (placebo)
Locations: North Bay Eye Associates, Inc., Petaluma, California, United States
Levenson Eye Associates, Inc, Jacksonville, Florida, United States
Chicago Corneal Consultants, Hoffman Estates, Illinois, United States
Price Vision Group, Indianapolis, Indiana, United States
Tauber Eye Center, Kansas City, Missouri, United States
... and 2 other locations.
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
Status: Recruiting
Last Changed: Nov 05, 2020
First Received: Jun 19, 2020
Disease(s): Fuchs Endothelial Corneal Dystrophy
Intervention(s): N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Status: Recruiting
Last Changed: Nov 24, 2020
First Received: Jan 31, 2020
Disease(s): Fuchs' Endothelial Corneal Dystrophy
Intervention(s): K-321 Solution, Placebo Solution
Locations: Jules Stein Eye Institute, Los Angeles, California, United States
Byers Eye Institute at Stanford, Palo Alto, California, United States
Sacramento Eye Consultants, Sacramento, California, United States
Gorovoy MD Eye Specialists, Fort Myers, Florida, United States
Northwestern Medicine, Chicago, Illinois, United States
... and 27 other locations.
Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens
Status: Completed
Last Changed: Mar 04, 2008
First Received: Nov 04, 1999
Disease(s): Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Locations: National Eye Institute (NEI), Bethesda, Maryland, United States